The Governing Council provides strategic inputs and direction towards the management and implementation of NBRIC.
Kiran Mazumdar-Shaw is the Chairperson and Managing Director of Biocon, Asia’s leading bio-pharmaceuticals enterprise. Named among TIME magazine is 100 most influential people in the world, she is recognized as a global thought leader for Biotechnology. Under her stewardship, Biocon has evolved since its inception in 1978 from an industrial enzymes company to a fully integrated, innovation-led, emerging global biopharmaceutical enterprise committed to reduce therapy costs of chronic conditions like diabetes, cancer, and autoimmune diseases.As a global influencer, she is ranked among ‘World’s 25 Most Influential People in Biopharma’ by Fierce Biotech, Forbes magazine’s ‘World’s 100 Most Powerful Women’ and Fortune’s ‘Top 25 Most Powerful Women in Asia-Pacific.’ She has been recognized as the only Indian on Forbes’ list of ‘World’s Self-Made Women Billionaires.’ She has been featured in ‘The Worldview 100 List’ of the most influential visionaries by Scientific American magazine and named among the ‘100 Leading Global Thinkers’ by Foreign Policy magazine.Most recently, she is elected as a full-term member of the Board of Trustees of The MIT Corporation, USA.
Govindarajan Padmanabhan is a celebrated biochemist and biotechnologist, known for his work on malaria. In a career spanning 50 years, he has mentored several students, helped establish start-ups and several research institutes.He has been appointed as the chancellor of the Central University of Tamil Nadu (CUTN), Tiruvarur. In the early years of his research, he primarily worked in the transcriptional regulation of Eukaryotic genes in the liver. He was interested in elucidating the multifaceted role of heme in cellular processes.He has also been interested in vaccine development. His team was successful in showing theantimalarial property of Curcumin and its efficacy in combination therapy in 2004. He succeeded Prof. C. N. R. Rao as IISc director in 1994.
An academic (professor of engineering and computer science for 23 years) turned entrepreneur. As an academic he got PhD in the mathematics of decision sciences (aka operations research) at MIT in 1982. He taught and conducted research in the computational mathematics of optimization, geometry, logic and biology at Purdue University (1982-1993) and the Indian Institute of Science (1992-2005).In 1998, he joined hands with kindred spirits to create the Simputer (a handheld computer). He also co-founded PicoPetaSimputers which commercialized the Simputer to create the AmidaSimputer. He is co-founder and director of Strand Life Sciences a life science informatics company based in Bangalore, India. We captured around 30% of the global market for analytics software in research biology for the various “Omics” – genomics, proteomics, metabolomics, etc.Strand Life Sciencesis a global personalized medicine company using clinical genomics for oncology and inherited disorders.
Dr. Mahesh Bhalhat joined syngene as Chief Operating Officer (COO) in July, 2019. Before Syngene he was in ShanthaBiotechnics, a Sanofi company, where he was responsible for all manufacturing operations, supply chain, engineering projects, HSE, manufacturing excellence and administrative services.In a career spanning over 25 years in the field of biotechnology and biologics, Dr.Bhalgat is recognised for his contribution to the commercialization of diagnostic kits, biopharmaceuticals and WHO pre-qualification of vaccines. He has rich experience in diverse areas of biotechnology such as biotherapeutics, vaccines, ag-biotech, and research reagents and has been associated with companies such as Amgen, Monsanto, Celera Genomics, Thermo Fisher, Biological E.A Ph.D. in Medicinal Chemistry from the University of Utah, he is the Co-Chair of CII’s National Committee of Biotechnology as well as a member of the Biomeriux Scientific Advisory Board, France, United States Pharmacopeia, GCBA committee and the Indian Pharmacopeial Commission.
Dr. Kavita is Mission Director -National Biopharma Mission of Department of Biotechnology. She was Programme Director at Multi Vaccines Development Program ( MVDP), not-for-profit research society under the Indian Societies Registration Act 1860 by the collaborative efforts of Department of Biotechnology, Ministry of Science and Technology, Government of India ; International Centre for Genetic Engineering and Biotechnology, New Delhi and PATH – Malaria Vaccine Initiative, USA and Honorary Member of Research Steering Group @ Wellcome Supported Pre-clinical evaluation of Dengue Subunit Tetravalent Vaccine. She was Cofounder and Director, Sakosh Biotech Private Limited. She has served as head for clinical research in companies like Fortis Clinical Research Ltd., GVK Biosciences, Ranbaxy, and Shantha Biotech. She has studied Vaccinology @ FondationMérieux and Unviersity De Geneva
She finished her Executive Program in Business Management @ Indian Institute of Management, Calcutta. Dr. Kavita pursued her MBBS in Medicine at Govt Medical College, Patiala and MD in Microbiology from Postgraduate Institute of Medical Education and Research.
Dr. Saiyed is the Chief Executive Officer and Director of C-CAMP. In his role as CEO, he oversees all the operations and is responsible for the growth of the organisation. He has been instrumental in building an innovation and entrepreneurship ecosystem at C-CAMP and is actively involved in promoting innovation in lifescience / healthcare by supporting translation of discoveries to application, entrepreneurship, technology development and mentoring start-ups. He also heads the Discovery to Innovation Accelerator program as well as the Intellectual Property and Technology Transfer Office at C-CAMP.
Dr. Saiyed’s initial training has been in neurosciences, where he received his PhD from Max-Planck Institute for Brain Research, Germany and followed it up by postdoctoral training at University of California San Francisco (UCSF). At the same time, he also underwent training in management for Biotech and Innovation from QB3 at UCSC, UC Berkeley and UC Davis. In the bay area, he also served as a Management Consultant with QB3 New Biotech Venture Consulting a
Dr. Saiyed is also an Adjunct Faculty at Amrita Institute – School of Biotechnology and working on Neurodegeneration.